Picture of Anna-Maria

Anna-Maria Fontrier, MSc

Anna-Maria is a Senior Health Technology Assessment (HTA) consultant. She has extensive knowledge and experience in pharmaceutical policy, including pricing, reimbursement and value assessment systems in Europe, Canada, Australia and the Middle East and North Africa region.

Anna-Maria completed her MSc in International Health Policy at the London School of Economics (LSE) and her BSc in Chemistry and Business Administration at Aston University. She is about to complete her PhD at LSE, where she researched the implications of HTA processes for market entry of new medicines and medicines treating rare diseases in the European Union, the United Kingdom and Canada.

Before joining the Symmetron team, Anna-Maria worked for several years as a senior researcher at the Medical Technology Research Group of LSE Health. She was actively involved in the management and research of numerous consultancy projects for both public and private institutions including the pharmaceutical industry, governmental bodies and the European Commission. Past work experience includes roles at the Health Reform Support Program for Greece and Novartis Hellas.

Fontrier A-M, Kanavos P. Do reimbursement recommendations by the Canadian Agency for Drugs and Technology in Health translate into coverage decisions for orphan drugs in the Canadian province of Ontario?, Value in Health (2023)

Fontrier, A.M., 2022. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations. Social Science & Medicine, 306, p.115119.

Fontrier, A.M., Visintin, E. and Kanavos, P., 2021. Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries. PharmacoEconomics-open, pp.1-14.

Fontrier, A.M., Gill, J. and Kanavos, P., 2019. International impact of external reference pricing: should national policy-makers care? The European Journal of Health Economics, 20(8), pp.1147-1164.

Kanavos, P., Fontrier, A.M., Gill, J. and Efthymiadou, O., 2020. Does external reference pricing deliver what it promises? Evidence on its impact at the national level. The European Journal of Health Economics, 21(1), pp.129-151.

Gill, J., Fontrier, A.M., Kyriopoulos, D. and Kanavos, P., 2019. Variations in external reference pricing implementation: does it matter for public policy?. The European Journal of Health Economics, 20(9), pp.1375-1397.

Kanavos, P., Kamphuis, B.W., Fontrier, A.M., Parkin, G.C., Saleh, S. and Akhras, K.S., 2020. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?. Health Policy, 124(12), pp.1297-1309.

Kanavos, P., Tzouma, V., Fontrier, A.M. and Souliotis, K., 2019. Implementing health technology assessment (HTA) in Greece: Myths, reality and cautionary tales. Arch Hellen Med, 37, pp.444-451.